Equities research analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report issued on Monday. The brokerage set a “sell” rating on the stock.
Oragenics Stock Down 0.9 %
NYSE:OGEN opened at $1.05 on Monday. Oragenics has a 1 year low of $0.97 and a 1 year high of $7.74. The firm has a 50 day moving average price of $1.47. The company has a market capitalization of $4.70 million, a PE ratio of -0.12 and a beta of 0.50.
Oragenics (NYSE:OGEN – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- Transportation Stocks Investing
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- How Can Investors Benefit From After-Hours Trading
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Conference Calls and Individual Investors
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.